Milrinone is a phosphodiesterase inhibitor, a cardiotonic drug with positive inotropic and vasodilating effects, which can be used to treat acute or chronic refractory congestive heart failure.
Millinone is a cardiotropic drug, belonging to phosphodiesterase inhibitors. By inhibiting phosphodiesterase, the drug can increase the concentration of cyclic adenosine phosphate and calcium in cardiomyocytes, thereby effectively strengthening myocardial contractility and increasing cardiac output, so as to exert positive muscle strength. In addition, Milrinone can also play a vasodilator role by directly acting on the small arteries.
milrinone supports ventricular functioning of the heart by decreasing the degradation of cAMP and thus increasing phosphorylation levels of many components in the heart that contribute to contractility and heart rate. Milrinone use following cardiac surgery has been under some debate because of the potential increase risk of postoperative atrial arrhythmias. However, in the short term milrinone has been deemed beneficial to those experiencing heart failure and an effective therapy to maintain heart function following cardiac surgeries. There is no evidence of any long term beneficial effects on survival.
Milrinone, is a medication used in patients who have heart failure. It is a phosphodiesterase 3 inhibitor that works to increase the heart's contractility and decrease pulmonary vascular resistance. Milrinone also works to vasodilate which helps alleviate increased pressures (afterload) on the heart, thus improving its pumping action. While it has been used in people with heart failure for many years, recent studies suggest that milrinone may exhibit some negative side effects that have caused some debate about its use clinically.
Overall, milrinone supports ventricular functioning of the heart by decreasing the degradation of cAMP and thus increasing phosphorylation levels of many components in the heart that contribute to contractility and heart rate. Milrinone use following cardiac surgery has been under some debate because of the potential increase risk of postoperative atrial arrhythmias. However, in the short term milrinone has been deemed beneficial to those experiencing heart failure and an effective therapy to maintain heart function following cardiac surgeries. There is no evidence of any long term beneficial effects on survival.
Tuna viwanda vingi vya ubora wa juu na ushirikiano wa kina, ambavyo vinaweza kukupa bidhaa za ubora wa juu na bei za ushindani. Na tunaweza pia kutoa punguzo kwa ununuzi wa wingi.Na tunashirikiana na makampuni mengi ya kitaalamu ya usambazaji wa mizigo, yanaweza kuwasilisha bidhaa kwa usalama na kwa urahisi mikononi mwako. Wakati wa uwasilishaji ni takriban siku 3-20 baada ya uthibitisho wa malipo.
Uchambuzi
|
Vipimo
|
Matokeo
|
Test method
|
Physical Description
|
|
|
|
Mwonekano
|
White Powder
|
White Powder |
Visual
|
Harufu
|
Characteristic
|
Characteristic
|
Organoleptic
|
Particle size
|
90% pass 80 mesh
|
90% pass 80 mesh
|
80 Mesh Screen
|
Chemical Tests
|
|
|
|
Assay (Lutein)
|
99%
|
90.15%
|
HPLC
|
Loss on drying
|
5.0% Max
|
1.82%
|
5g/105ºC/2hrs
|
Ash Contents
|
5.0% Max
|
1.12%
|
2g/525ºC/3hrs
|
Residual Solvents
|
50.0 ppm, Only Ethanol
|
<30.0 ppm
|
/
|
Heavy metals
|
5.0 ppm Max
|
<3.0 ppm
|
AAS
|
Lead
|
3.0 ppm Max
|
<1.0 ppm
|
AAS
|
Arsenic
|
3.0 ppm Max
|
<1.0 ppm
|
AAS
|
Microbiology Control
|
|
|
|
Total Bacteria Count
|
1,000cfu/g Max
|
<280cfu/g
|
AOAC
|
Yeast & Mold
|
100cfu/g Max
|
<10cfu/g
|
AOAC
|
Coliform
|
30.0 MPN/g Max
|
<3.0 MPN/g
|
AOAC
|
Hitimisho
|
Complies with the standards.
|
||
General Status
|
Non-GMO, ISO Certificated.
|
Milrinone is a PDE3 (phosphodiesterase 3) inhibitor that exhibits vasodilator and positive inotropic effects. Milrinone's positive inotropic activity can be inhibited by carbachol (sc-202092). Research indicates that Milrinone can increase platelets and enhance cAMP levels. Milrinone is an inhibitor of PDE3A and PDE3B.
Milrinone, commonly known and marketed as the drug Primacor, is a medication used in patients suffering from heart failure. Milrinone is a phosphodiesterase 3 inhibitor that works to increase the heart's contractility. Milrinone also works to vasodilate vessels which helps alleviate increased pressures (afterload) on the heart, thus improving its pumping action. Milrinone has been used in those suffering from heart failure for many years.
1. Je, wewe ni kiwanda au kampuni ya biashara?
Sisi ni compnay kuunganisha sekta na biashara, kutoa one-stop service.OEM inaweza kukubalika.
2. Je, unatoa sampuli? Je, ni bure au ya ziada?
Sampuli zisizolipishwa. Ada ya mizigo ya sampuli inahitaji kulipwa na wewe.
3. Je, una vyeti vyovyote vinavyohusiana na udhibiti wa ubora?
Cheti cha ISO 9001:2008 ili kuhakikisha ubora.
4. Nitoe nini ili kupata nukuu?
Pls tufahamishe aina ya bidhaa unayohitaji, kiasi cha agizo, anwani na mahitaji maalum. Nukuu itafanywa kwa kumbukumbu yako kwa wakati.
5. Je, unapendelea njia gani ya malipo? Ni masharti ya aina gani yanakubaliwa?
Sheria na Masharti Yanayokubaliwa: FOB,CFR,CIF,EXW;
Sarafu ya Malipo Inayokubalika:USD;
Aina ya Malipo Yanayokubaliwa: T/T,Western Union; Paypal, Uhakikisho wa Biashara.
Lugha Inasemwa:Kiingereza.
Kategoria za bidhaa